HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1

A. Omrani, T. Van Der Vaart, E. Mientjes, G. M. Van Woerden, M. R. Hojjati, K. W. Li, D. H. Gutmann, C. N. Levelt, A. B. Smit, A. J. Silva, S. A. Kushner, Y. Elgersma

Research output: Contribution to journalArticlepeer-review

38 Scopus citations

Abstract

Cognitive impairments are a major clinical feature of the common neurogenetic disease neurofibromatosis type 1 (NF1). Previous studies have demonstrated that increased neuronal inhibition underlies the learning deficits in NF1, however, the molecular mechanism underlying this cell-type specificity has remained unknown. Here, we identify an interneuron-specific attenuation of hyperpolarization-activated cyclic nucleotide-gated (HCN) current as the cause for increased inhibition in Nf1 mutants. Mechanistically, we demonstrate that HCN1 is a novel NF1-interacting protein for which loss of NF1 results in a concomitant increase of interneuron excitability. Furthermore, the HCN channel agonist lamotrigine rescued the electrophysiological and cognitive deficits in two independent Nf1 mouse models, thereby establishing the importance of HCN channel dysfunction in NF1. Together, our results provide detailed mechanistic insights into the pathophysiology of NF1-associated cognitive defects, and identify a novel target for clinical drug development.

Original languageEnglish
Pages (from-to)1311-1321
Number of pages11
JournalMolecular Psychiatry
Volume20
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint Dive into the research topics of 'HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1'. Together they form a unique fingerprint.

Cite this